McLaughlin P J, Elwood N J, Russell S M, Andrew S M, McKenzie I F
Department of Immunology, University of Liverpool, U.K.
Anticancer Res. 1992 Jul-Aug;12(4):1243-6.
Four murine monoclonal antibodies were produced against human recombinant tumor necrosis factor alpha (TNF alpha). They were characterized with respect to specificity, affinity, neutralization of in vitro L929 cell killing by TNF alpha and neutralization of the in vivo biological activities of toxicity and tumor necrosis. The monoclonal antibodies were further investigated for reactivity with TNF alpha in Western blotting. All four monoclonal antibodies reacted with human TNF alpha. One of then also reacted with mouse TNF alpha and human TNF beta (lymphotoxin), this antibody did not neutralize in vitro cytotoxicity or in vitro biological activities of TNF alpha. The other antibodies were neutralizing and it appeared that, in some cases, the systemic toxic effect of TNF alpha could be reversed by anti-TNF alpha monoclonal antibody therapy while retaining significant anti-tumour effects.
制备了四种针对人重组肿瘤坏死因子α（TNFα）的鼠单克隆抗体。对它们的特异性、亲和力、体外中和TNFα对L929细胞的杀伤作用以及体内毒性和肿瘤坏死生物活性的中和作用进行了表征。进一步研究了这些单克隆抗体在蛋白质免疫印迹法中与TNFα的反应性。所有四种单克隆抗体均与人TNFα反应。其中一种还与小鼠TNFα和人TNFβ（淋巴毒素）反应，该抗体不能中和TNFα的体外细胞毒性或体外生物活性。其他抗体具有中和作用，并且在某些情况下，TNFα的全身毒性作用似乎可以通过抗TNFα单克隆抗体治疗逆转，同时保留显著的抗肿瘤作用。
